Citigroup Inc Keros Therapeutics, Inc. Transaction History
Citigroup Inc
- $163 Billion
- Q4 2024
A detailed history of Citigroup Inc transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Citigroup Inc holds 54,423 shares of KROS stock, worth $561,645. This represents 0.0% of its overall portfolio holdings.
Number of Shares
54,423
Previous 23,381
132.77%
Holding current value
$561,645
Previous $1.36 Million
36.55%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding KROS
# of Institutions
172Shares Held
29.9MCall Options Held
341KPut Options Held
102K-
Black Rock Inc. New York, NY2.51MShares$25.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.96MShares$20.2 Million0.0% of portfolio
-
Braidwell LP Stamford, CT1.89MShares$19.6 Million1.68% of portfolio
-
Darwin Global Management, Ltd. St. Helier, Y91.69MShares$17.4 Million2.53% of portfolio
-
State Street Corp Boston, MA1.2MShares$12.4 Million0.0% of portfolio
About Keros Therapeutics, Inc.
- Ticker KROS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,757,000
- Market Cap $266M
- Description
- Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...